PRINCETON, N.J., Oct. 11 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries announced today the availability of a new survey on pharmaceutical Observational Research, the fourth in an on-going series. The survey is open to all in the industry with an interest in observational research and can be accessed here through October 31, 2010.
Jeff Trotter, Executive Vice President, Phase IV Development, and creator of the survey, remarked, "Pharmaceutical companies are increasingly looking to prospective Observational Research for compiling real world data on post-approval clinical performance, economic value, patient quality-of-life, and product safety. While the scientific community excels at designing and executing controlled clinical trials, there may be less appreciation for the value of observational studies. The goal of the survey is to identify underlying issues in order to move toward more appropriately-designed studies that improve the understanding of product performance among clients, regulators, policymakers, physicians and patients."
Previous surveys have revealed that drug development organizations can benefit from broader cross-functional collaboration and consensus on the strategy for observational research. The latest survey will continue to track evolving trends.
The results of this survey, plus the findings identified in previous surveys, are expected to be released in November. If you are interested in receiving the findings report or receiving more information on pharmaceutical observational research, please contact firstname.lastname@example.org.
About PharmaNet Development Group, Inc.
PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2300 employees in 33 countries and more than 38 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at www.pharmanet.com.
SOURCE PharmaNet Development Group, Inc.